抄録
To establish an acceptable postoperative chemotherapy for lung cancer, 2 mg/m2/day of CDDP was infused continuously with 300 or 400 mg/day of UFT. Hydration was not performed during CDDP administration. We treated 32 patients. The concentrations of the protein-bound platinum (total-Pt= T-Pt) (μg/ml) in serum from weeks 1, 2, 3, 4, 5, and 6 of the treatment were 0.249±0.143, 0.402±0.155, 0.494±0.142, 0.567±0.158, 0.574±0.132, and 0.567±0.125, respectively. After two weeks of treatment, the T-Pt augmented significantly (p<0.05) as compared with those of after one week. Non protein-bound-platinum was not detected during this period. Area under the concentration-time curve (AUC) of the T-Pt (μg·hr/ml) from weeks 1, 2, 3, 4, 5, and 6 were 22.36±11.09, 76.09±35.81, 152.62±59.10, 232.74±73.65, 334.22±75.16, and 438.27±95.96, respectively. After six weeks of treatment, the concentrations and AUCs of the T-Pt seemed to be sufficient for an anticancer treatment. The side effects associated with this treatment were grade I and II anorexia in six cases and leukopenia in three cases. The treatment was interrupted because of grade III anorexia in one case (3 weeks) and vomiting in one case (3 weeks), However, recovery from the side effects was immediate. We think this treatment contributes to an improvement in the patient's postoperative quality of life.
